Genomics, Circuits, and Pathways in Clinical Neuropsychiatry

<p>Section 1 The Genome Tools and Methods</p> <p>1. The Newly Emerging View of the Genome</p> <p>Stephan Sanders</p> <p>2. Genetic Epidmeiology</p> <p>Kathleen Ries Merikangas</p> <p>3. Common Variation</p> <p>Mark Daly</p> <p>4. Rare/Structural Variation</p> <p>Daniel Barrera and Jonathan Sebat </p> <p>5. Epigenetics and Epigenomics</p> <p>Eric J. Nestler and John Greally </p> <p>6. Bioinformatics</p> <p>Shaun Purcell</p> <p>7. Imaging Genomics</p> <p>Paul Matthew Thompson</p> <p>8. Stem Cell Technology and Genomics</p> <p>Alysson Renato Muotri</p> <p>9. Association Strategies</p> <p>Benjamin M. Neale</p> <p>10. The promise of Systems Biology</p> <p>Eric Schadt</p> <p>11. Gene networks in neuropsychiatric disease</p> <p>Daniel Geschwind</p> <p>12. Mosaicism</p> <p>Christopher A. Walsh and Saumya Shekhar Jamuar </p> <p>Section 2 A new neuroanatomy</p> <p>13. Mapping the Molecular Landscape of the Human Brain</p> <p>Nenad Sestan</p> <p>14. Studying Circuits</p> <p>Stephan Lammel and Robert Malenka </p> <p>15. Electrophysiological Measurement of Circuits</p> <p>Srikantan S. Nagarajan</p> <p>16. Imaging the Circuitry of the Human Brain</p> <p>Michael Greicius</p> <p>17. Neuroimaging Advances in Alzheimer’s Disease </p> <p>Daniel R. Schonhaut and Gil Rabinovici </p> <p>18. Progressive Supranuclear Palsy and Related Parkinsonian Disorders</p> <p>Jesse A. Brown and William Seeley </p> <p>19. The Anatomy of Basal Ganglia Circuitry of Behavior</p> <p>Nicholas Au Yong, Adrienne M. Keener, Yvette Bordelon, Carlos Portera-Cailliau and Nader Pouratian </p> <p>20. Brainstem Circuitry of Behavior</p> <p>Helmut Heisen</p> <p>21. Apathy – Basal Ganglia, Frontal Circuits</p> <p>Mario F. Mendez</p> <p>22. Emotion Circuitry</p> <p>Robert Wayne Levenson</p> <p>23. Delusions</p> <p>Georges Naasan</p> <p>24. Hallucinations</p> <p>Dennis Velakoulis</p> <p>Section 3 Clinical Phenomenology</p> <p>25. Intro: Risk Overlap Among Disorders</p> <p>Patrick Sullivan</p> <p>26. The conundrum of Clinical Characterization RDOC/ICD-10/DSM</p> <p>Bruce N. Cuthbert</p> <p>27. Schizophrenia</p> <p>Aiden Corvin</p> <p>28. Psychosis</p> <p>Raquel E. Gur and Ruben Gur </p> <p>29. ASD</p> <p>Rebecca Ann Muhle, Stephan Sanders, Hannah Reed and Matthew William State </p> <p>30. Bipolar Disorder</p> <p>Nelson B. Freimer, Carrie E. Bearden and Peter Zandi </p> <p>31. MDD</p> <p>David C. Glahn</p> <p>32. Speech and Language Disorders</p> <p>Marilu Gorno-Tempini</p> <p>33. Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia</p> <p>Suzee Eurie Lee and Jennifer S. Yokoyama </p> <p>34. Alzheimer’s</p> <p>Rudy Tanzi</p> <p>35. PTSD</p> <p>Kerry Ressler</p> <p>36. Neurodevelopmental syndromes</p> <p>Elliott Sherr</p> <p>37. Epilepsies</p> <p>Ryan S. Dhindsa, Daniel Lowenstein and David Goldstein </p> <p>38. Substance Abuse</p> <p>Nii Addy</p> <p>39. Neuroimmunology</p> <p>Emmanuel Mignot</p> <p>40. Brain Tumors</p> <p>Vanessa Clark and Murat Günel </p> <p>41. White Matter Disorders</p> <p>Michael David Geschwind and Brianne Magouirk Bettcher </p> <p>42. ALS</p> <p>Elena Ratti and James Berry </p> <p>43. Eating Disorders</p> <p>Cynthia M. Bulik and Garret Stuber </p> <p>Section 4 Clinical Translation and Drug Development</p> <p>44. Pharmacogenomics</p> <p>Roy H. Perlis</p>